ArticleAnnals of surgery1993
Neurotensin regulates growth of human pancreatic cancer.
Article in Annals of surgery, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 68 citations in OpenAlex.
- Role of endogenous somatostatin in postprandial hypersecretion of neurotensin in patients after gastrectomy.Annals of surgery · 1997Trial
- Reshaping [Pharmaceutics · 2025Article
- Neurotensin modulates ovarian vascular permeability via adherens junctions.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway.American journal of cancer research · 2024Article
- Side-Chain Modified [International journal of molecular sciences · 2023Article
- Toward Stability Enhancement of NTSPharmaceutics · 2023Article
- Neurotensin receptor 1 signaling promotes pancreatic cancer progression.Molecular oncology · 2021Article
- Optimizing the Profile of [International journal of molecular sciences · 2020Article
- Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands.Pharmaceutics · 2020Article
- GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.British journal of pharmacology · 2020Review
- The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review.Cell communication and signaling : CCS · 2020Review
- Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.American journal of cancer research · 2015Article
- Protein kinase D enzymes: novel kinase targets in pancreatic cancer.Expert review of gastroenterology & hepatology · 2015Review
- Evidence for the importance of personalized molecular profiling in pancreatic cancer.Pancreas · 2014Article
- Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia.World journal of gastroenterology · 2013Article
- Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells.Molecular oncology · 2009Article
- [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.European journal of nuclear medicine and molecular imaging · 2007Article
- Gut peptide receptor expression in human pancreatic cancers.Annals of surgery · 2000Article
- Article
- Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24.The Biochemical journal · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe effect of neurotensin (NT) on in vitro-growth of human pancreatic cancer cells (MIA PaCa-2) was examined. Furthermore, the intracellular signal-transduction pathways by which neurotensin regulates growth of MIA PaCa-2 cells were determined. SUMMARY BACKGROUND DATA: NT is trophic for normal rat pancreas, but the effect of NT on growth of human pancreatic cancer is not known.
methodsEffects of NT (10(-12) to 10(-6) mol/l) on growth of MIA PaCa-2 cells were determined by both count of cell numbers and 3H-thymidine incorporation. Action of NT on phosphatidylinositol (PI) hydrolysis, cyclic AMP production, and intracellular calcium level were determined by conventional methods. The effects of 8-bromo-cyclic AMP and prostaglandin E2 on cell growth were determined.
resultsLow concentrations of NT (10(-12) to 10(-9) mol/l) stimulated growth in a dose-dependent manner, but higher concentrations of NT (10(-8) to 10(-6) mol/l) did not stimulate growth of MIA PaCa-2 cells. NT (10(-12) to 10(-6) mol/l) stimulated PI hydrolysis and increased intracellular calcium levels in a dose-dependent manner. High concentrations of NT (10(-8) to 10(-6) mol/l) stimulated production of cyclic AMP in a dose-dependent manner. 8-bromo-cyclic AMP inhibited growth of MIA PaCa-2 cells; prostaglandin E2 did not affect growth of MIA PaCa-2 cells.
conclusionsNT stimulates growth of MIA PaCa-2 cells through stimulation of PI hydrolysis and mobilization of calcium. Stimulation of the cyclic AMP pathway by high concentrations of NT abolishes the growth-stimulatory effect of NT that is mediated through PI hydrolysis or calcium mobilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.